Pfizer And BioNTech Announce Plan To Expand Phase 3 Covid-19 Vaccine Trial By 50% To 44000 Participants
A Tale Of Three Potential Vaccines – How They Stack Up In The Race For Coronavirus Prevention
A Day After Encouraging Phase I/II Clinical Trial, Pfizer-BioNTech Announces A $1.95 Billion Covid-19 Vaccine Order From U.S. Government
